Immunome (IMNM) Receives Buy Recommendation from Truist Securities with 32.90% Upside Potential

Truist Securities has initiated coverage of Immunome (IMNM) with a Buy recommendation, with an average one-year price target of $24.48/share, a 32.90% increase from its latest reported closing price of $18.42/share. The projected annual revenue for Immunome is $0MM, a decrease of 100.00%, and the projected annual non-GAAP EPS is $6.55. The fund sentiment is bullish, with 312 funds or institutions reporting positions in Immunome and an average portfolio weight of 0.16%.